EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Emergent BioSolutions Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCM Products | $511.50M | $401.90M | $456.70M | $474.30M | $506.00M | $511.00M | $509.80M | $531.00M | $464.50M | $565.40M | $447.20M | – | 66.4% | +1.1% |
| Commercial Products | $208.60M | $223.70M | $226.10M | $252.80M | $273.20M | $325.70M | $398.90M | $444.90M | $491.70M | $509.60M | $497.30M | – | 27.1% | -23.6% |
| Products | – | – | – | – | – | – | – | – | – | – | – | $1.00B | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and services sales, net | $742.30M | $645.80M | $705.20M | $750.70M | $812.50M | $930.30M | $1.01B | – | – | – | – | – | 96.4% | -8.6% |
| MCM Product sales | $511.50M | $401.90M | $456.70M | $474.30M | $506.00M | $511.00M | $509.80M | $531.00M | $464.50M | $565.40M | $447.20M | – | 66.4% | +1.1% |
| Commercial Product sales | $208.60M | $223.70M | $226.10M | $252.80M | $273.20M | $325.70M | $398.90M | $444.90M | $491.70M | $509.60M | $497.30M | – | 27.1% | -23.6% |
| All other revenue | $50.10M | $51.20M | $60.10M | $61.80M | $72.40M | $128.70M | $134.90M | – | – | – | – | – | 6.5% | -30.8% |
| Contracts and grants | $27.90M | $31.00M | $37.70M | $38.20M | $39.10M | $35.10M | $30.00M | $31.30M | $27.80M | $27.80M | $26.30M | $26.70M | 3.6% | -28.6% |
| Products | – | – | – | – | – | – | $908.70M | $975.90M | $956.20M | $1.08B | $944.50M | $1.00B | – | – |
| Service | – | – | – | – | – | – | $103.50M | $117.30M | $116.60M | $78.50M | $72.80M | $69.40M | – | – |
By region
From the segment and revenue-disaggregation notes of Emergent BioSolutions's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.